Payment overview · 2025
General Payments
$62,753.19
133 reported records · 15 companies
Healthcare provider profile · identity verified
Haidar Yassin, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · PHOENIX, AZ · NPI 1659532000
Verified facts
What the public records show
CMS Open Payments records show Haidar Yassin, M.D. received $62,753.19 in general payments during 2025 across 133 reported records.
Boston Scientific Corporation accounted for 68.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 417 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $43,032.44 | 68.6% | 39 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $13,070.19 | 20.8% | 49 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $2,229.57 | 3.5% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $1,488.65 | 2.4% | 14 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$893.99 | 1.4% | 8 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $677.47 | 1.1% | 7 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $413.27 | 0.7% | 3 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $304.03 | 0.5% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $180.69 | 0.3% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $125.00 | 0.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $118.77 | 0.2% | 1 | 2025 |
| B. Braun Interventional Systems Inc. | Unresolved — no canonical attribution shown | $104.85 | 0.2% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $81.54 | 0.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.73 | 0.0% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $15.00 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $35,550.00 | 14 |
| Travel and Lodging | $10,784.93 | 22 |
| Food and Beverage | $8,293.26 | 94 |
| Consulting Fee | $8,125.00 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $42,238.03 | 27 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $9,881.10 | 11 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $2,229.57 | 4 | 2025 |
Source payment records
|
|||||
| TRICLIP Normalized: triclip |
Device | Abbott Laboratories | $1,009.89 | 10 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $862.13 | 9 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $756.95 | 7 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $460.29 | 9 | 2025 |
Source payment records
|
|||||
| EVOQUE Normalized: evoque |
Device | Edwards Lifesciences Corporation | $431.17 | 8 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $413.27 | 3 | 2025 |
Source payment records
|
|||||
| PORTICO Normalized: portico |
Device | Abbott Laboratories | $193.95 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $180.69 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $180.69 | 1 | 2025 |
Source payment records
|
|||||
| GORE CARDIOFORM Septal Occluder Normalized: gore cardioform septal occluder |
Device | W. L. Gore & Associates, Inc. | $178.16 | 1 | 2025 |
Source payment records
|
|||||
| General - Atherectomy Normalized: general atherectomy |
Device | Boston Scientific Corporation | $167.06 | 1 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $151.56 | 1 | 2025 |
Source payment records
|
|||||
| PASCAL Normalized: pascal |
Device | Edwards Lifesciences Corporation | $148.50 | 5 | 2025 |
Source payment records
|
|||||
| THE EDWARDS SAPIEN 3 VALVE WITH ALTERRA ADAPTIVE PRESTENT SYSTEM Normalized: the edwards sapien 3 valve with alterra adaptive prestent system |
Device | Edwards Lifesciences Corporation | $145.16 | 2 | 2025 |
Source payment records
|
|||||
| THORATEC HEARTMATE 3 LVAS IMPLANT KIT Normalized: thoratec heartmate 3 lvas implant kit |
Device | Abbott Laboratories | $144.34 | 1 | 2025 |
Source payment records
|
|||||
| APOLLOTM Normalized: apollotm |
Device | Medtronic, Inc. | $137.04 | 1 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis Normalized: gore excluder thoracoabdominal branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $125.87 | 1 | 2025 |
Source payment records
|
|||||
| Laser Parts Other Normalized: laser parts other |
Device | Philips North America LLC | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $122.50 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $118.77 | 1 | 2025 |
Source payment records
|
|||||
| NIT-OCCLUD PDA Normalized: nit occlud pda |
Device | B. Braun Interventional Systems Inc. | $104.85 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $81.54 | 1 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $59.08 | 1 | 2025 |
Source payment records
|
|||||
| XIENCE SKYPOINT Normalized: xience skypoint |
Device | Abbott Laboratories | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| VersaCross Access Solution Normalized: versacross access solution |
Device | Boston Scientific Corporation | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $15.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
417 | 128 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1051 | 345 |
| Metoprolol Succinate | Metoprolol Succinate | 600 | 198 |
| Lisinopril | Lisinopril | 547 | 170 |
| Losartan Potassium | Losartan Potassium | 466 | 155 |
| Amlodipine Besylate | Amlodipine Besylate | 449 | 157 |
| Eliquis | Apixaban | 417 | 128 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 370 | 136 |
| Metoprolol Tartrate | Metoprolol Tartrate | 350 | 113 |
| Clopidogrel | Clopidogrel Bisulfate | 331 | 142 |
| Furosemide | Furosemide | 330 | 126 |
| Carvedilol | Carvedilol | 256 | 92 |
| Hydrochlorothiazide | Hydrochlorothiazide | 203 | 74 |
| Xarelto | Rivaroxaban | 184 | 55 |
| Ezetimibe | Ezetimibe | 174 | 60 |
| Pravastatin Sodium | Pravastatin Sodium | 108 | 34 |
| Simvastatin | Simvastatin | 97 | 36 |
| Sotalol | Sotalol Hcl | 96 | 28 |
| Potassium Chloride | Potassium Chloride | 92 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 32 |
| Spironolactone | Spironolactone | 79 | 32 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 71 | 21 |
| Warfarin Sodium | Warfarin Sodium | 68 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | 17 |
| Valsartan | Valsartan | 48 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 20 |
| Repatha Sureclick | Evolocumab | 44 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 42 | 17 |
| Atenolol | Atenolol | 41 | 14 |
| Terazosin Hcl | Terazosin Hcl | 41 | suppressed |
| Entresto | Sacubitril/Valsartan | 40 | suppressed |
| Nifedipine Er | Nifedipine | 38 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 37 | suppressed |
| Digoxin | Digoxin | 35 | 12 |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Brilinta | Ticagrelor | 33 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Fenofibrate | Fenofibrate | 29 | 12 |
| Jardiance | Empagliflozin | 27 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 12 |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $62,753.19 · 133 records | Boston Scientific Corporation | APOLLOTM, AVVIGO Guidance System, CAMZYOS, COREVALVE EVOLUT R, CT THROMBECTOMY SYSTEM KIT, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), EVOQUE, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, FFRct, FLOWTRIEVER CATHETER, S, GORE CARDIOFORM Septal Occluder, GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, General - Atherectomy, Indigo System, LEQVIO, Laser Parts Other, LifeVest, MITRACLIP, NIT-OCCLUD PDA, PASCAL, PORTICO, SAPIEN 3 Ultra RESILIA, SYMPHONY CATHETER, THE EDWARDS SAPIEN 3 VALVE WITH ALTERRA ADAPTIVE PRESTENT SYSTEM, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, TRICLIP, VersaCross Access Solution, WATCHMAN Access System, WATCHMAN FLX, XIENCE SKYPOINT | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error